Uniloc

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Uniloc

Property Description
Active Ingredient Atenolol
Form Film-Coated Tablet (Oral Dosage)
Pharmacological Class Cardioselective beta-Blocker
Common Use Management of high blood pressure and chest pain
Origin Synthetic Compound

1. Uniloc: Identity, Classification, and Active Ingredient

Uniloc is a prescription-only medication whose active ingredient is the chemical substance Atenolol. It belongs to the class of drugs known as cardioselective beta-adrenergic blocking agents, or beta-blockers, designed to modulate the cardiovascular system.

As a single-ingredient, synthetic compound, Uniloc contains Atenolol as its core substance, which is responsible for its pharmacological activity. Atenolol acts specifically as a cardioselective beta1 receptor antagonist, meaning it primarily targets the beta-1 receptors found predominantly in the heart muscle. This preferential action is recognized for its role in managing cardiac function, a key differentiation from older, non-selective beta-blockers. The active substance is utilized for its efficacy in addressing key cardiovascular health needs.


2. Form and General Therapeutic Purpose

Uniloc is manufactured and administered as an oral dosage form, specifically a film-coated tablet, intended for the systemic delivery of the active ingredient via the oral route of administration. The synthetic compound Atenolol (CAS 38166-03-3) is classified as both an antihypertensive and antiarrhythmic agent. This classification reflects the drug's role in managing high blood pressure and stabilizing heart rhythm.

The general purpose of this medication is to moderate the effects of stress hormones on the heart, resulting in the heart beating more slowly and with less force. This fundamental physiological change helps to decrease the workload on the heart muscle and is essential for achieving overall stability in the cardiovascular system, particularly in contexts involving elevated arterial pressure.

Regulatory References

  1. Atenolol: MedlinePlus Drug Information
  2. WHO List of Essential Medicines
  3. Atenolol Drug Label (DailyMed/NIH)

What side effects are possible with Uniloc?

Uniloc: Possible Side Effects and Safety Information

Serious Safety Information

Uniloc carries a Boxed Warning on its labeling, which is the most serious warning required by the U.S. Food and Drug Administration (FDA). This warning is based on findings from a large safety clinical trial that reported an increased risk of heart-related death and death from all causes in patients treated with Uniloc compared to those treated with allopurinol (a comparator drug).

Patients with a history of heart problems or stroke should be made aware of this potential safety concern and discuss all treatment risks and benefits with a healthcare professional.

Common Adverse Reactions

The most commonly reported side effects observed in clinical trials, categorized by frequency, include:

  • Common: Nausea, skin rash, joint pain, gout flares, and abnormal liver problems.

Warnings and Restrictions

The product labeling highlights that while the overall risk of major adverse cardiovascular events (MACE) was not increased in the trial, the individual outcomes of heart-related death and all-cause mortality were increased. Due to this finding, the drug label requires particular caution and consideration when prescribing. The serious cardiovascular risk structures the overall safety profile, emphasizing the need for ongoing safety monitoring.

Overdose and Emergency Response

Overdose and when to seek help

The following information details the officially documented manifestations and required emergency actions in the event of an overdose of Uniloc (Atenolol), as described in government regulatory documents.


Documented Manifestations and Outcomes

Classification Official Regulatory Information
Documented Manifestations Extreme bradycardia (very slow heart rate), severe hypotension (very low blood pressure), atrioventricular block, fainting, confusion, and weakness are documented signs.
Serious Outcomes Overdose can lead to overt cardiac failure, cardiogenic shock, bronchospasm, seizures, and coma.
Population Note Hypoglycemia (low blood sugar) is specifically documented as a risk in children following this type of overdose.

Required Emergency Actions

The regulator mandates specific actions when an overdose is suspected. Individuals must seek immediate medical help right away. It is required to call emergency services if the affected person has collapsed, has had a seizure, is experiencing trouble breathing, or cannot be awakened.

Official management procedures include gastric decontamination (e.g., activated charcoal) and monitoring vital signs. While no specific antidote is universally known, targeted supportive treatments, such as glucagon and atropine, are used by medical professionals to manage toxicity. Hospital monitoring, including an ECG and blood tests, is required for ongoing assessment.

Therapeutic Uses of Uniloc

What Uniloc Treats: Main Uses and Benefits

This medication is commonly used to help with symptomatic management following a heart attack, is applied in addressing high blood pressure, and is also relevant for easing symptoms related to angina (chest pain). It is considered relevant across therapeutic domains where additional symptomatic support is needed to help ease discomfort or tension associated with cardiovascular conditions. The medication supports the management of symptoms related to heightened physiological activity, which may include an irregular or fast pulse, and is relevant when supportive symptom management is appropriate.

This medicine is commonly used to help with conditions involving episodic or fluctuating manifestations, and is applied to help manage symptoms associated with severe, recurrent migraine attacks. This is part of symptomatic management in situations where symptoms create noticeable functional strain.

“It provides supportive relief when symptoms become more disruptive during flare-ups, and may assist with maintaining functional stability.”

Quick Fact: Relief for Recurrent Headaches This medicine is commonly used to help with conditions presenting with episodic or recurrent manifestations of severe head pain. It may assist with maintaining functional stability and contributing to improved comfort during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility for Uniloc (Atenolol) Use

Official regulatory documents define specific populations who are permitted, restricted, or prohibited from using Uniloc. This information is critical for determining eligibility.


Absolute Contraindications

Uniloc must not be used by patients with the following severe conditions, as formally stated in the drug's regulatory labeling:

  • Sinus Bradycardia (slow heart rate)
  • Heart Block greater than first degree (e.g., second- or third-degree AV block)
  • Cardiogenic Shock or Overt Cardiac Failure (uncompensated heart failure)
  • Metabolic Acidosis
  • Untreated Pheochromocytoma
  • Hypersensitivity to atenolol or any components of the medicine

Population Restrictions and Cautions

Category Eligibility Rule Restriction Status
Pediatric Patients Safety and effectiveness not established Not Recommended (leq 18 years old)
Renal Impairment Severe renal function impairment ( CrCl < 35 mL/min) Restricted (requires dosage limitation)
Bronchospastic Diseases Conditions like asthma or severe COPD Avoided/Caution (risk of increased airway resistance)
Pregnancy/Lactation Excreted into breast milk; potential for fetal/neonatal risk Not Recommended

Older Adults are permitted to use Uniloc, but regulatory documents advise a cautious approach, often requiring lower starting doses due to the potential for reduced kidney function. Patients with diabetes or thyrotoxicosis also require caution as the medicine may mask symptoms of hypoglycemia or hyperthyroidism, respectively.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Uniloc (Atenolol) as described in government regulatory documents.


Interaction Classifications and Restrictions

Interaction Type Interacting Agent Documented Outcome or Restriction
Additive Cardiovascular Effect Verapamil, Diltiazem (Calcium Channel Blockers), Amiodarone, Digoxin (Antiarrhythmics) Increased risk of severe bradycardia, hypotension, and atrioventricular block.
Antagonism of Effect NSAIDs (e.g., Indomethacin) May reduce the antihypertensive effect of Uniloc.
Procedural Restriction Clonidine (Antihypertensive Agent) The beta-blocker must be withdrawn several days before the gradual discontinuation of Clonidine to prevent rebound hypertension.

Pharmacokinetic and Timing Constraints

Administration of Aluminum Hydroxide (Antacids) decreases the plasma concentration of Uniloc by inhibiting gastrointestinal absorption. A mandatory timing separation of at least two hours is required between these substances. Ingestion of Uniloc with food is also documented to reduce its oral bioavailability by approximately 20%. The drug may mask the symptom of tachycardia associated with hypoglycemia when co-administered with Insulin or Oral Antidiabetic Agents. Since Uniloc is eliminated primarily by renal excretion, there is a risk of significant accumulation and heightened exposure in patients with impaired kidney function, which influences overall interaction risk.

Mechanism of Action

Uniloc's Targeted Receptor and Enzyme Modulation

Uniloc exerts its primary action by precisely engaging a defined receptor or enzyme system, functioning to immediately modulate its activity (either blocking or activating). This targeted molecular interaction represents the initial step in the drug's mechanism, influencing the targeted system's activity pattern.

Dampening Signal Transduction Pathways

Following target engagement, Uniloc modifies signal transduction pathways associated with heightened physiological responses. By controlling the flow of molecular messages within this specific cascade, the drug dampens excessive signaling, a consequence which limits the escalation of activity in the affected system.

Influencing Physiological Regulatory Systems

The modulation of the pathway ultimately translates into a functional influence on core central or peripheral regulatory systems. This mechanistic domain results in the modulation of overactive physiological processes, resulting in an adjustment of the overall systemic balance.

Dosage and Administration Information

Uniloc is primarily administered via the oral route as a film-coated tablet for long-term chronic management. The oral dose is typically taken once daily, and the tablets may be consumed with or without food, as described in product specifications. For most chronic conditions, therapy usually begins at 50 mg once daily, progressing to a standard maintenance dose of 50 mg to 100 mg daily.


Official Administration Protocols

For acute management, such as the initial phases of a heart attack, the administration protocol requires a brief series of intravenous injections in a supervised hospital setting, followed immediately by a transition to the oral tablet, where a maintenance regimen of 100 mg daily is established. This two-step process highlights the two distinct contexts of use.


Population-Specific Adjustments

Established instructions mandate specific dosage adjustments based on patient status. For older adults, a lower starting dose, such as 25 mg once daily, may be used. In cases of renal impairment, the maximum daily dose must be reduced significantly based on creatinine clearance, sometimes limited to 25 mg or 50 mg on alternate days.

Uniloc is intended for long-term therapy. If discontinuation is necessary, the dosage must be gradually withdrawn (tapered) over a period of one to two weeks, following established protocols. If a dose is missed, a double dose should not be taken.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Uniloc

Evidence for Use in Managing High Blood Pressure

Uniloc (Atenolol) was evaluated in numerous large Randomized Controlled Trials (RCTs) and systematic reviews exploring its use in adults with high blood pressure, or hypertension. These studies monitored outcomes related to systemic or functional imbalance, specifically focusing on measurements of systolic and diastolic blood pressure readings. The research examined whether use was associated with long-term outcomes, such as the occurrence of stroke, myocardial infarction, and overall cardiovascular mortality.

Studies comparing Atenolol against a placebo reported measurements related to reduction in blood pressure readings. Research also described patterns related to the occurrence of certain serious cardiovascular events compared to no treatment. However, when Atenolol was studied against other high blood pressure medications, findings described varying results regarding its association with all-cause mortality and stroke prevention. The research includes comparative studies against other classes of high blood pressure medications for long-term cardiovascular outcomes.

Evidence for Use Following a Heart Attack (Post-Myocardial Infarction)

Research on Prophylaxis for Severe, Recurrent Migraine Attacks

Uniloc was studied for use in patients experiencing conditions involving periods of heightened symptoms, specifically as a prophylactic (preventive) measure for severe, recurrent migraine attacks. Randomized Controlled Trials and systematic reviews research examined how frequently patients experienced headaches and how severe those headaches were, using patient-reported outcomes describing perceived discomfort.

Studies report how symptoms evolved in the observed populations, often tracking the change in the average number of migraine days per month. The findings were mixed regarding the measured changes in episode frequency and severity across all studies. This area of research often includes smaller sample sizes, and Atenolol is grouped with other beta-blockers in systematic reviews. Data for certain groups remain insufficient regarding long-term, sustained relief.

Key Studies & References

  1. WHO List of Essential Medicines (Atenolol inclusion for cardiovascular health needs)
  2. NIH MedlinePlus Drug Information: Atenolol (Common uses in high blood pressure, angina, and post-heart attack management)

Frequently Asked Questions (FAQ)

Common questions about Uniloc (FAQ)

Q: How quickly does Uniloc start working?

A: Official documents indicate that the beta-blocking effects of the medicine are typically noticeable within one hour after taking an oral dose. The medication often reaches its maximum initial effect within two to four hours of administration.

Q: What is the usual time it takes to see the full effect of Uniloc?

A: Studies described in regulatory documents show that the main effects of the medicine persist for at least 24 hours following a single daily dose. Consistent blood pressure measurements are often described in research as stabilizing over time with continued use of the treatment regimen.

Q: What are the most common side effects of Uniloc?

A: Regulatory summaries cite commonly reported adverse events beyond those categorized as 'common' in clinical trials. These may include feeling fatigue (tiredness), dizziness, a slow heartbeat (bradycardia), and low blood pressure (hypotension).

Q: Can Uniloc be used while drinking alcohol?

A: Official product information describes that alcohol may lead to additive effects that lower blood pressure when used with the active ingredient. Official documents describe that this combination may increase the potential for symptoms such as dizziness or lightheadedness due to these additive effects.

Q: Does the food I eat affect how Uniloc works?

A: According to the official prescribing information, consuming the medicine with food may reduce the amount of medicine absorbed by the body by approximately 20%. Despite this change in absorption, official instructions state that the medicine can generally be taken with or without food.

Q: Can I crush or break Uniloc tablets?

A: Official product instructions advise that the ability to split or alter tablets often depends on the specific form of the tablet and whether it features a score line for dividing. Official documents indicate that patients should refer to the specific administration instructions provided by a healthcare professional.

Q: Are there different forms of Uniloc (e.g., tablet, liquid)?

A: The medicine is primarily supplied as an oral film-coated tablet. It is also described in regulatory documents as an intravenous injection that is used for specific, supervised uses in acute settings.

Q: Why do official documents describe a possible risk of [rare adverse event] with Uniloc?

A: Regulatory documents are required to provide a comprehensive list of all reported adverse events, including those that are rare. This disclosure ensures that patients and prescribers are fully informed about the entire safety profile observed across all clinical trials and post-marketing experience.

Q: Is Uniloc the same type of medicine as other treatments for [Condition]?

A: Uniloc is formally classified as a cardioselective beta-adrenergic blocking agent, or beta-blocker. This classification defines its action on specific receptors, which makes it pharmacologically distinct from other types of medications used for similar conditions.

Q: Does Uniloc cause weight change?

A: Regulatory summaries and safety data have described weight gain as a potential side effect associated with the active ingredient and other older beta-blockers. This change is typically observed during the initial months of use.

Q: Can Uniloc affect my sleep?

A: The official product labeling for the medicine lists sleep disorders and disturbances as reported adverse effects. If a person experiences these effects, they are part of the known safety profile.

Q: Is it normal to feel [mild side effect] when first starting Uniloc?

A: Patient information derived from regulatory sources often describes that side effects can be more noticeable when first starting the medicine. Official patient information describes that side effects may become less pronounced as a person's body adjusts to the medicine.

Q: What is the difference between the generic and brand name Uniloc?

A: Regulatory agencies, such as the FDA, generally require the generic form of the active ingredient to be bioequivalent to the brand-name product. This means the generic version is expected to work in the same way in the body regarding absorption and overall effect.

Q: What information is available about Uniloc in official research studies?

A: Official documents contain summaries of evidence from clinical studies, which often include Randomized Controlled Trials (RCTs). These studies examine the drug's use for high blood pressure, chest pain, and management following a heart attack.

Q: Why is my prescription for Uniloc a different strength than what my friend uses?

A: Regulatory guidelines state that the dosage of the medicine is typically individualized. The chosen strength is based on specific factors, including the patient’s condition, overall response to treatment, age, and kidney function.

Q: Can Uniloc make me feel dizzy or light-headed?

A: Yes, dizziness and feeling lightheaded are specifically listed among the commonly reported adverse effects in the official product labeling. Official labeling notes these effects may be observed.

Q: Is Uniloc addictive?

A: The active ingredient in Uniloc is not classified as a controlled substance by regulatory bodies in the United States. Official drug labels do not list addiction or dependency as known risks of the medicine.

Q: Does Uniloc have an effect on mental clarity or focus?

A: Official documents list central nervous system effects, such as confusion, dizziness, and fatigue, as reported adverse events. These effects may indirectly influence a person's perceived mental clarity or focus.

How should Uniloc be stored and disposed of?

Storage and Disposal of Uniloc (Atenolol)

The medicine must be stored strictly according to official regulatory requirements to maintain product quality and ensure safety.

Storage and Protection Disposal Guidelines
Temperature: Store at controlled room temperature, generally below 25 C or 30 C. Wastewater: Do not flush the tablets down the toilet or pour them into a drain.
Environment: Protect from light and moisture; avoid storing in a bathroom. Unused/Expired: Use a drug take-back program at a local collection site (preferred method).
Container: Keep in the original container and ensure it is tightly closed to prevent contamination. Household Trash: If a take-back program is unavailable, mix the medicine with an undesirable substance (e.g., dirt) in a sealed bag and then discard in the trash.

Child Safety: All medication must be kept out of the reach and sight of children at all times.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Uniloc found in:

A-Z Index: